



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



SGC0946 (trifluoroacetate salt)

Item No. 42012

Formal Name: 5-bromo-7-[[5-deoxy-5-[[[3-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]propyl](1-methylethyl)amino]-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, trifluoroacetate salt

MF: C₂₈H₄₀BrN₇O₄ • XCF₃COOH


FW: 618.6

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥ years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SGC0946 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the SGC0946 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. SGC0946 (trifluoroacetate salt) is sparingly soluble (1-10 mg/ml) in ethanol and slightly soluble (0.1-1 mg/ml) in DMSO.

Description

SGC0946 is an inhibitor of the non-SET domain-containing methyltransferase DOT1L (IC₅₀ = 0.3 nM).¹ It is selective for DOT1L over a panel of 12 additional protein methyltransferases, DNA methyltransferase 1 (DNMT1), and a panel of 29 receptors and ion channels. SGC0946 reduces the levels of dimethylated lysine 79 on histone 3 (H3K79me2) in MCF-10A breast cancer cells (IC₅₀ = 8.8 nM). It selectively reduces the viability of isolated human cord blood cells transformed with an *MLL-AF9* fusion oncogene over those transformed with a *TLS-ERG* fusion oncogene when used at concentrations of 1 and 5 μM. Adoptive transfer of isolated human CD3⁺ T cells pre-incubated with SGC0946 (0.5 μM) prevents weight loss, increases survival, and reduces hepatic and colonic lymphocyte infiltration in a xenogeneic mouse model of graft versus host disease (GVHD).²

References

1. Yu, W., Chory, E.J., Wernimont, A.K., *et al.* Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. *Nat. Commun.* **3**, 1288 (2012).
2. Kagoya, Y., Nakatsugawa, M., Saso, K., *et al.* DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. *Nat. Commun.* **9**(1), 1915 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/23/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM